Failures to disclose government funding associated with Doudna patents related to “Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

PDF version of letter to NIH. Failure2disclose-Doudna-patents-12oct2020 October 12, 2020 Michelle Bulls Director Office of Policy for Extramural Research Administration (OPERA) National Institutes of Health Via Email: michelle.bulls@nih.gov RE: Failures to disclose government funding associated with patents related to “Methods… Continue Reading

KEI Comments to the NIH on Exclusive License of AAV Technology to Children’s Medical Research Institute in Australia

Knowledge Ecology International (KEI) submitted comments on Wednesday July 14, 2021 to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Adeno-Associated Virus Polynucleotides, Polypeptides and Virions” (86 FR 34246). The rights to technology… Continue Reading

KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy

Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading

KEI Comments on NIH Exclusive License to Panacea for Gene Therapy

On Friday July 9, 2021, Knowledge Ecology International submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Delivery of a Corrective Glucose-6-Phosphatase-Alpha Gene to Treat Glycogen Storage Disease Type 1a (GSD-Ia)… Continue Reading